Product Strategies for Non-Oral Hematology Drugs

DUBLIN, March 22, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Product Strategies for Non-Oral Hematology Drugs" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The administration of non-oral drugs for the treatment of blood disorders has evolved over the past ten years to include heparin analogs and recombinant proteins designed to treat chronic conditions that are life threatening and often debilitating illnesses. As the availability of drugs based on new APIs or molecular entities has grown, the product strategies in the marketplace have increased in specificity and sophistication.

The chronic nature of many blood diseases and the growing trend toward patient self-administration for non-oral medications is requiring drug developers and product managers to refine their product strategy at the highest level, with formulation and device selection decisions being made prior to the clinical trial phase of development.

Key Topics Covered:

Executive Summary

Therapeutic Hematology Market Dynamics - Evolution in Drug Therapies - Growth of Self-Administration - Key Markets for Hematology Drug Therapeutics - Anemia - Deep Vein Thrombosis - Heart Valve Prosthesis - Neutropenia - Pulmonary Embolism - Competitive Landscape - Opportunities and Risks

Non-Oral Hematology Drug Formulation and Packaging Factors - Extended Release Formulations - Packaging - Vial vs Prefilled Device - Vial Strategies - Prefilled Device Strategies - Prefilled Syringes - Autoinjectors - Pen Injectors

Non-Oral Hematology Drug Administration Factors - Dosing - Dose Frequency - Route of Administration - Intravenous - Subcutaneous

Non-Oral Hematology Drugs - Product Analysis and Market Data

See the rest here:
Product Strategies for Non-Oral Hematology Drugs